Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2022 Jul;49(8):2949-2959.
doi: 10.1007/s00259-022-05773-1. Epub 2022 Mar 28.

The radiomics-based tumor heterogeneity adds incremental value to the existing prognostic models for predicting outcome in localized clear cell renal cell carcinoma: a multicenter study

Guangjie Yang #  1 , Pei Nie #  2 , Lei Yan #  1 , Mingxin Zhang #  3 , Yangyang Wang  1 , Lianzi Zhao  4 , Mingyao Li  5 , Fei Xie  3 , Haizhu Xie  6 , Xianjun Li  7 , Fawei Xiang  7 , Nan Wang  8 , Nan Cheng  9 , Xia Zhao  10 , Ning Wang  11 , Yicong Wang  12 , Chengcheng Chen  13 , Canhua Yun  14 , Jingjing Cui  15 , Shaofeng Duan  16 , Ran Zhang  17 , Dapeng Hao  18 , Ximing Wang  19 , Zhenguang Wang  20 , Haitao Niu  21
Affiliations
Multicenter Study

The radiomics-based tumor heterogeneity adds incremental value to the existing prognostic models for predicting outcome in localized clear cell renal cell carcinoma: a multicenter study

Guangjie Yang et al. Eur J Nucl Med Mol Imaging. 2022 Jul.

Abstract

Purpose: Tumor heterogeneity, which is associated with poor outcomes, has not been exhibited in the University of California, Los Angeles, Integrated Staging System (UISS), and the Stage, Size, Grade and Necrosis (SSIGN) scores. Radiomics allows an in-depth characterization of heterogeneity across the tumor, but its incremental value to the existing prognostic models for clear cell renal cell carcinoma (ccRCC) outcome is unknown. The purpose of this study was to evaluate the association between the radiomics-based tumor heterogeneity and postoperative risk of recurrence in localized ccRCC, and to assess its incremental value to UISS and SSIGN.

Methods: A multicenter 866 ccRCC patients derived from 12 Chinese hospitals were studied. The endpoint was recurrence-free survival (RFS). A CT-based radiomics signature (RS) was developed and assessed in the whole cohort and in the subgroups stratified by UISS and SSIGN. Two combined nomograms, the R-UISS (combining RS and UISS) and R-SSIGN (combining RS and SSIGN), were developed. The incremental value of RS to UISS and SSIGN in RFS prediction was evaluated. R statistical software was used for statistics.

Results: Patients with low radiomics scores were 4.44 times more likely to experience recurrence than those with high radiomics scores (P<0.001). Stratified analysis suggested the association is significant among low- and intermediate-risk patients identified by UISS and SSIGN. The R-UISS and R-SSIGN showed better predictive capability than UISS and SSIGN did with higher C-indices (R-UISS vs. UISS, 0.74 vs. 0.64; R-SSIGN vs. SSIGN, 0.78 vs. 0.76) and higher clinical net benefit.

Conclusions: The radiomics-based tumor heterogeneity can predict outcome and add incremental value to the existing prognostic models in localized ccRCC patients. Incorporating radiomics-based tumor heterogeneity in ccRCC prognostic models may provide the opportunity to better surveillance and adjuvant clinical trial design.

Keywords: Clear cell renal cell carcinoma; Heterogeneity; Outcome; Radiomics; SSIGN; UISS.

PubMed Disclaimer

References

    1. Volpe A, Patard JJ. Prognostic factors in renal cell carcinoma. World J Urol. 2010;28:319–27. - DOI
    1. Stewart SB, Thompson RH, Psutka SP, Cheville JC, Lohse CM, Boorjian SA, et al. Evaluation of the National Comprehensive Cancer Network and American Urological Association renal cell carcinoma surveillance guidelines. J Clin Oncol. 2014;32:4059–65. - DOI
    1. Zhang J, Fujimoto J, Zhang J, Wedge DC, Song X, Zhang J, et al. Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science. 2014;346:256–9. - DOI
    1. Rutman AM, Kuo MD. Radiogenomics: creating a link between molecular diagnostics and diagnostic imaging. Eur J Radiol. 2009;70:232–41. - DOI
    1. de Leon AD, Kapur P, Pedrosa I. Radiomics in kidney cancer: MR imaging. Magn Reson Imaging Clin N Am. 2019;27:1–13. - DOI

Publication types

LinkOut - more resources